RxDoctor Payments Data

Alan Chanales, MD

Pulmonary Disease · Rockville, MDNPI 1093719023

Payments from drug & device makers

$4,341in general payments, 2019–2025

Across 223 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$747
  • Mallinckrodt Hospital Products Inc.$429
  • Mylan Specialty L.p.$351
  • Sanofi$193
  • plus $421 from 9 others

What the payments were for

  • Food & beverage$4,09294%
  • Education$2496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,341 in reported general payments places this provider in the 60th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$182,963
Medicare patients
495
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter496$450,486
Breo ElliptaFluticasone/Vilanterol353$187,893
Arnuity ElliptaFluticasone Furoate482$159,462
Dupixent PenDupilumab27$140,191
OfevNintedanib Esylate12$139,427
Dupixent SyringeDupilumab13$57,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$32,901
Fluticasone-SalmeterolFluticasone Propion/Salmeterol148$25,553
Spiriva RespimatTiotropium Bromide20$20,131
Incruse ElliptaUmeclidinium Bromide47$18,378
Fluticasone Propionate721$15,414
Qvar RedihalerBeclomethasone Dipropionate17$12,082
SymbicortBudesonide/Formoterol Fumarate43$11,936
Azelastine Hcl234$10,765
DuleraMometasone/Formoterol14$9,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$1,021$816,2181,378 claims
Boehringer IngelheimOfev, Spiriva Respimat$27$159,55832 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$1,179$51,133107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →